All In Biotech

Drug Trial Radar · NCT06769633

Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Than 6 Years Old

Last checked: Nov 20, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Jan 2, 2025

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
Collaborators
Fortrea
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 2 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in younger DMD Patients. * Planned screening duration: approximately 4 weeks * Planned Core Treatment duration: approximately 48 weeks * Planned Extension Treatment duration: approximately 96 weeks * Planned Follow Up duration: approximately 4 weeks (± 7 days) * Total duration of study participation: up to 151 weeks (ie, 37-38 months)

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • Givinostat HydrochlorideDrug

    Cohort 1 - from 4 to 6 years old

  • Givinostat Hydrochloride - Cohort 2Drug

    Cohort 2 - from 2 to 4 years old

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Phase: Cohort 1 - Change from baseline of the pharmacokinetic (PK) parameter Area under the concentration-time curve from dosing (time 0) to time t at steady state (AUC0-T,ss).Time frame: Baseline up to week 48
  2. Core Phase: Cohort 1 - Change from baseline of the pharmacokinetic (PK) parameter maximum plasma concentration at steady state (Cmax,ss).Time frame: Baseline up to week 48
  3. Core Phase: Cohort 1 - Change from baseline of the pharmacokinetic (PK) parameter elimination half-life (t1/2) assessed after at least 7 days of dosing.Time frame: Baseline up to week 48
  4. Core Phase: Cohort 2 - Change from baseline of the pharmacokinetic (PK) parameter Area under the concentration-time curve from dosing (time 0) to time t at steady state (AUC0-T,ss).Time frame: Baseline up to week 48
  5. Core Phase: Cohort 2 - Change from baseline of the pharmacokinetic (PK) parameter maximum plasma concentration at steady state (Cmax,ss).Time frame: Baseline up to week 48
  6. Core Phase: Cohort 2 - Change from baseline of the pharmacokinetic (PK) parameter elimination half-life (t1/2) assessed after at least 7 days of dosingTime frame: Baseline up to week 48
  7. Extension Phase: Type, incidence, and severity of treatment-emergent adverse eventsTime frame: postbaseline up to Week 144
  8. Extension Phase: Proportion of patients experiencing treatment-emergent adverse eventsTime frame: postbaseline up to Week 144

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Queen Fabiola Children's University Hospital HUDERF

    Brussels, Belgium · Recruiting

  • Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscolar Omnicenter

    Milan, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesù

    Roma, Italy · Recruiting

  • Policlinico Universitario Agostino Gemelli - Università Cattolica del Sacro Cuore

    Roma, Italy · Recruiting

  • Leids Universitair Medisch Centrum (LUMC)

    Leiden, Netherlands · Recruiting

  • Leeds Teaching Hospital NHS Trust

    Leeds, England, United Kingdom · Not yet recruiting

  • Great Ormond Street Hospital - GOSH

    London, England, United Kingdom · Not yet recruiting

  • Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University

    Newcastle upon Tyne, England, United Kingdom · Recruiting

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, England, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.